Vaccination News Home Page            Scandals            subscribe Vaccination NewsLetter

http://bmj.com/cgi/content/full/326/7397/1018

PDF of this article Email this article to a friend Respond to this article Read responses to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Dunn, N. Alert me when: New articles cite this article

Collections under which this article appears: 10 minute consultations Adverse drug reactions

BMJ 2003;326:1018 ( 10 May )

Primary care

10-minute consultation
 

Adverse drug event

Nick Dunn, senior lecturer in primary medical care. 

School of Medicine, University of Southampton, Southampton SO16 5ST

nick.dunn@soton.ac.uk

A 72 year old woman on holiday in your area consults you four weeks after starting treatment with a non-steroidal anti-inflammatory drug (NSAID) for her painful knee. She complains of "a reaction" to the drug. She says she has had problems with similar drugs previously, but this drug is new and supposedly has fewer side effects. She says she has been feeling weak and giddy and has developed a widespread itchy skin rash. She tells you, however, that the drug was effective as a pain reliever. You find that she also has angina and high blood pressure.
 

	What issues you should cover

Top What issues you should... What you should do

History Take a detailed history of the presenting complaint. The exact timing of events is important, as 80% of adverse drug reactions (usually type Athat is, pharmacologically predictable) occur in the first month of treatment. Establish whether she had weakness or giddiness to any extent before she began taking the drug. Has she had or does she presently have any intercurrent illness (for example, viral infection)? Has she any symptoms that indicate gastrointestinal, heart, or lung disease? If the rash started within a few days of starting the drug, and she was otherwise well, the chance of a drug reaction is higher. Has she any history of dyspepsia, peptic ulceration, asthma, heart failure, or renal failure? Any of these may be exacerbated by NSAIDs and might result in her non-specific symptoms.

Previous treatment Has she ever had any similar rash or gastrointestinal bleeding when she has taken any NSAID in the past? Any such history would increase the chance of her present symptoms being a reaction to drugs. Is she taking low dose aspirin for her angina? This will increase the chance of gastrointestinal bleeding.

Examination All NSAIDs can cause gastrointestinal bleeding, especially in elderly people. Some of these drugs are more dangerous than others, but it is important to exclude such bleeding (palpate the epigastrium, take pulse and blood pressure, and check for anaemia; rectal examination for melaena may be indicated). Look for any abnormal lung signs, as well as evidence of oedema of the ankle. Consider renal function tests. Rash as a drug reaction can be multifaceted and difficult to diagnose, but the commonest manifestations are probably exanthema, urticaria, and generalised pruritus.
 

	What you should do

Top What issues you should... What you should do

• Although her presenting symptoms may not allow a conclusive diagnosis, the risk-benefit analysis of this situation will depend on the clinical assessment of the likelihood of an adverse drug reaction. Adverse drug reactions are commoner in old people and in women. Nearly a quarter of adverse drug reactions officially reported in the United Kingdom are due to NSAIDs. Gastrointestinal bleeding in old people is associated with considerable mortality. Thus, if in doubt it is safer to stop the drug. The clinical result of stopping treatment should be recorded.
• Supply an alternative analgesic if the NSAID is stopped.
• The rash may persist for some time after stopping the drug and may require symptomatic treatment.
• All drug adverse events should be reported through the appropriate channels. These vary from country to country (see box for the UK situation). France, for example, has a system of 31 regional pharmacovigilance centres, each of which collects and records reports of adverse drug events from healthcare professionals. These reports are then collated in a national database. In the United States case reports are sent either to the manufacturer, which forwards the report to the Food and Drug Administration, or to the FDA directly. Most of these systems are voluntarybut they are vital if adverse reactions to drugs already on the market are to be detected before serious damage is done.

	Footnotes

The series is edited by general practitioners Ann McPherson and Deborah Waller (ann.mcpherson@dphpc.ox.ac.uk)

The BMJ welcomes contributions from general practitioners to the series

This is part of a series of occasional articles on common problems in primary care

© 2003 BMJ Publishing Group Ltd

Rapid responses:

Read all Rapid responses

Regional ADR monitoring centres exist in the UK.

Anthony R Cox

bmj.com, 8 May 2003 [Full text]

Learning from Adverse Drug Events

John Sandars

bmj.com, 9 May 2003 [Full text]

The Pharmasearch Network in Italy

Aurelio A. Sessa, et al.

bmj.com, 10 May 2003 [Full text]

Adverse drug reactions — defining terms

Jeff Aronson

bmj.com, 16 May 2003 [Full text]

PDF of this article Email this article to a friend Respond to this article Read responses to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Dunn, N. Alert me when: New articles cite this article

Collections under which this article appears: 10 minute consultations Adverse drug reactions

© 2003 BMJ Publishing Group Ltd

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.